4SC AG:4SC AG provides results for financial year 2022 and outlook for 2023
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that more than 80% of the events required to unblind the pivotal R…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that the 190th patient was enrolled into the pivotal RESMAIN study…
Die 4SC AG (4SC, FSE Prime Standard: VSC) hat heute bekannt gegeben, dass der 190. Patient in die zulassungsrelevante RE…
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinica…
Die 4SC AG (4SC, FSE Prime Standard: VSC) hat heute die Ergebnisse einer planmäßigen Überprüfung ihres Programms zur kli…
First Patient Enrolled in TURANDOT Study Evaluating Domatinostat in the Neoadjuvant Setting in Urothelial Carcinoma Comb…
4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2021, presenting all material developments up…
4SC today announced the initiation of a second clinical collaboration with the Netherlands Cancer Institute (NKI) on a p…
* Unabhängiges Data Safety Monitoring Board (DSMB) empfiehlt RESMAIN-Studie nach Überprüfung der kumulativen Sicherheits…